Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Philadelphia-negative myeloproliferative neoplasms MPNs such as Polycythemia Vera, Essential Thrombocythemia, and Prefibrotic Myelofibrosis are chronic blood cancers caused by mutations affecting blood cell growth. These diseases carry a high risk of blood clots, which can cause serious complications and death. Current treatments include low-dose aspirin, but blood clots still occur in some patients despite therapy. This trial aims to study whether direct oral anticoagulants DOACs, which have shown benefits in other cancer patients, might help prevent blood clots in MPN patients with a specific mutation called JAK2V617F. Participants will be randomly assigned to receive either a direct oral anticoagulanteither Apixaban 2.5 mg twice daily or Rivaroxaban 10 mg once dailyor low-dose aspirin 100 mg once daily. The choice of DOAC is up to the investigator. The treatments will be given to high-risk patients for up to 24 months to compare their effects on clot prevention. Throughout the study, participants will be closely monitored for any thrombotic or bleeding events. During the trial, researchers will track the time until any arterial or venous blood clots occur, as well as any major or clinically relevant bleeding events. They will also evaluate survival, adherence to therapy, quality of life, and healthcare costs related to these treatments. Participants will have regular follow-ups over 24 months, including assessments for heart rhythm problems and safety monitoring. This comprehensive approach aims to better understand the benefits and risks of DOACs compared to aspirin in preventing clots in MPN patients.
Actively Recruiting
Researchers are investigating treatments for acute myeloid leukemia AML, a blood cancer where myeloid cells grow uncontrollably. This study focuses on patients newly diagnosed with de novo AML who have intermediate or adverse genetic risk. It aims to compare the effects of a new drug combination, CPX-351, against standard intensive chemotherapy, especially in patients with certain genetic mutations linked to worse outcomes with current treatments. Participants will be randomly assigned to receive either CPX-351 or the standard chemotherapy regimen known as 73, which includes cytarabine and idarubicin. CPX-351 is given intravenously on specific days for induction and consolidation phases, while the standard chemotherapy follows a different schedule. The study will monitor how well these treatments reduce leukemia cells, using detailed genetic and flow cytometry tests, and explore biomarkers like P-gp activity. During the trial, participants will undergo bone marrow and blood tests to measure minimal residual disease MRD after treatment. Researchers will track remission rates, survival outcomes, side effects, quality of life, and changes in genetic markers for up to several years. Patients must be able to attend regular visits and blood sampling sessions throughout the study to support these evaluations.
Actively Recruiting
Researchers are studying a new way to give immunotherapy as maintenance treatment for patients with metastatic non-squamous lung cancer. This phase III clinical trial compares a pulse dosing schedule with a conventional dosing schedule to see if the less frequent pulse dosing is not worse than the standard treatment. The study focuses on pembrolizumab alone or combined with pemetrexed as the maintenance therapy after initial chemotherapy and immunotherapy induction. Participants are randomly assigned to one of two groups. In the Pulse arm, pembrolizumab 200 mg is given every 6 weeks, and pemetrexed 500 mgm is given every 3 weeks if there is no contraindication. In the Control arm, pembrolizumab is given either 200 mg every 3 weeks or 400 mg every 6 weeks, plus pemetrexed 500 mgm every 3 weeks when appropriate. This treatment is given after patients have completed 3 or 4 cycles of induction therapy with pembrolizumab plus platinum and pemetrexed. During the study, participants will be monitored for overall survival over 6 years, along with progression-free survival, response duration, quality of life using several questionnaires, treatment tolerance, and economic factors. Researchers will also perform population pharmacokinetic analyses and study the drugs effect on immune cells. Patients will undergo regular assessments including clinical evaluations and laboratory tests to track treatment effects and safety throughout the study period.
Actively Recruiting
Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.
Actively Recruiting
Fever is a common reason for children aged 3 months to 15 years to visit healthcare providers. It can be hard to tell if the fever is caused by a viral or bacterial infection just by examining the child, which sometimes requires additional tests like measuring C-reactive protein CRP. This study looks at using a capillary medical device to measure CRP directly in primary care to help reduce unnecessary referrals to emergency rooms and labs, improving care for febrile children and easing healthcare system burdens. The study compares two groups one using capillary CRP measurement with the ACTIM-CRP device and a control group without this intervention. Children are randomly assigned to these groups during their primary care visit when they have a fever that meets specific duration and severity conditions. The study runs from September 2025 to June 2027 and focuses on referral rates and other outcomes related to care pathways for febrile children. Participants will be involved in the study during their initial consultation and followed up for up to seven days to monitor referrals, antibiotic prescriptions, satisfaction of both general practitioners and parents, fever duration, and cost impacts. Data on complementary tests and healthcare usage will also be collected to understand the effects of using capillary CRP testing in primary care. The study aims to improve the efficiency and quality of care for children with fever.
Actively Recruiting
Disorders of blood sugar control are common in patients hospitalized for acute coronary syndrome ACS, with abnormal glucose levels found in about half of cases. High blood sugar is a major factor affecting outcomes after ACS, regardless of diabetes status. This research aims to evaluate the predictive value of various glucose measurements taken by a continuous glucose monitor over two weeks in patients with ACS. Participants will have the Freestyle Libre Pro iQ sensor applied upon admission to the cardiac intensive care unit. This device continuously and non-invasively measures interstitial glucose levels for up to 14 days. If necessary, a replacement sensor will be placed during hospitalization. The study focuses on the glucose data collected by this sensor and how it relates to cardiovascular events over one year. During the study, participants will be monitored using the sensor while receiving standard ACS care. Researchers will track cardiovascular events for 12 months and diabetes status at 2 and 12 months. The study collects detailed glucose variability data to assess its ability to predict major cardiovascular outcomes. Participation involves wearing the sensor during hospitalization and follow-up assessments over a year to evaluate health outcomes.
Actively Recruiting
Researchers are conducting a French national observational study to evaluate patients with HER2-negative early breast cancer who are treated with olaparib. The study aims to understand how many patients complete the full adjuvant olaparib treatment in a real-world setting. This study observes patients receiving olaparib as part of their standard care without assigning treatments. Participants are those diagnosed with HER2-negative early breast cancer and starting adjuvant olaparib based on their physicians decision. The study does not provide or assign treatments but follows patients who are prescribed olaparib in routine clinical practice. There are no comparison groups or placebo treatments in this observational study. During the study, researchers will monitor patients for up to 18 months to measure the proportion who complete the full olaparib treatment course. They will also collect information on BRCA mutation characteristics, medical history, and the timing of treatment discontinuation. Participants will be observed through routine care without additional interventions, allowing researchers to assess real-world treatment adherence and outcomes.
Actively Recruiting
Researchers are evaluating ziftomenib, a drug targeting the menin pathway, for treating adults with acute myeloid leukemia AML who have specific genetic mutations. This research involves two parallel phase 3 studies comparing ziftomenib combined with standard therapies against placebo plus standard therapies in patients who have not yet received AML treatment. The studies focus on patients with nucleophosmin 1 mutation NPM1-m or lysine-specific methyltransferase 2A rearranged KMT2A-r AML. In the Nonintensive Therapy Study, older or medically unfit patients receive either ziftomenib or placebo alongside venetoclax and azacitidine. In the Intensive Therapy Study, medically fit patients are randomized to receive ziftomenib or placebo combined with cytarabine and daunorubicin during induction, cytarabine plus ziftomenib or placebo during consolidation, and ziftomenib or placebo alone during maintenance. Both studies use a double-blind design where neither patients nor physicians know the treatment assignments. Participants will be monitored for up to 36 months after enrollment, with evaluations including overall survival, event-free survival, complete remission rates, and measurable residual disease in bone marrow. Safety and tolerability will be assessed through adverse event reports and drug concentration measurements. Patient-reported outcomes related to health will also be collected. The total study duration extends up to November 2031, allowing long-term follow-up and assessment of treatment effects.
Actively Recruiting
Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.
Actively Recruiting
This trial studies adults aged 18 to 60 with Acute Myeloid Leukemia AML to improve overall survival using risk-adapted treatment strategies. It is an open-label, multicenter phase IIIII study evaluating different chemotherapy regimens during induction, consolidation, and, when applicable, stem cell transplantation. The study also assesses graft versus host disease GvHD prevention methods after transplant in intermediate-risk patients. Participants receive one of several chemotherapy induction regimens comparing daunorubicin and high-dose idarubicin combined with cytarabine. Consolidation treatment compares high-dose versus intermediate-dose cytarabine, sometimes combined with drugs like vosaroxin, dexamethasone, or venetoclax. For patients receiving allogeneic stem cell transplant, GvHD prophylaxis is studied comparing standard treatments such as methotrexate and cyclosporine with mycophenolic acid combinations. Treatment cycles and doses vary based on the patients risk and response. Throughout the study, participants undergo bone marrow evaluations, blood tests, and heart function assessments to monitor response and safety. Researchers track overall survival over three years, incidence of acute GvHD within 100 days post-transplant, and disease-free survival at 18 months. Participants provide informed consent and are monitored regularly during treatment and follow-up periods. The study completion is planned for January 2032.
1-10 of 11
1